Disrupting androgen production of Leydig cells by resveratrol via direct inhibition of human and rat 3β-hydroxysteroid dehydrogenase
- 1 April 2014
- journal article
- Published by Elsevier in Toxicology Letters
- Vol. 226 (1) , 14-19
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and PharmacodynamicsCancer Prevention Research, 2011
- Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human SubjectsClinical Pharmacokinetics, 2010
- Effects of resveratrol analogs on steroidogenesis and mitochondrial function in rat Leydig cells in vitroJournal of Applied Toxicology, 2009
- The (+)- and (−)-gossypols potently inhibit both 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 in human and rat testesThe Journal of Steroid Biochemistry and Molecular Biology, 2009
- Effects of genistein, resveratrol, and quercetin on steroidogenesis and proliferation of MA-10 mouse Leydig tumor cellsJournal of Endocrinology, 2007
- Resveratrol improves health and survival of mice on a high-calorie dietNature, 2006
- Phytoestrogen Resveratrol Suppresses Steroidogenesis by Rat Adrenocortical Cells by Inhibiting Cytochrome P450 c21-HydroxylaseHormone Research in Paediatrics, 2005
- Sirtuin activators mimic caloric restriction and delay ageing in metazoansNature, 2004
- Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespanNature, 2003
- Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from GrapesScience, 1997